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Abstract
OBJECTIVE: To systematically investigate the safe-
ty of Xingxue® Shuxuening injection (SXN) in pre-
and post-marketing, and to ensure clinical drug
safety.
METHODS: Strict quality control in raw herb selec-
tion and production processes was adopted and
pharmacology research on SXN was performed by
the drug manufacturing company, Heilongjiang
ZBD Pharmaceutical Co., Ltd. We systematically re-
viewed the safety literature of Xingxue® SXN. Ad-
verse drug reaction (ADR) data of the drug, extract-
ed from Spontaneous Reporting System (SRS), and
clinical characters based on 20 hospital information
systems (HIS) in China, were analyzed. Large-scale
prospective safety monitoring and Risk Minimiza-
tion Action Plans (RiskMAPs) of Xingxue® SXN were
carried out.
RESULTS: The quality of SXN was stable and con-
trollable when it was produced. Drug toxicology
studies found no effect on rabbits with hemolytic
or condensed, local stimulation and muscle stimu-
lation, and no allergic reactions in guinea pigs. The
ADRs of Xingxue® SXN were dizziness, phlebitis,
and vomiting based on SRS data. The injection did
not conform to instructions in clinical practice
when we analyzed HIS database, and patient's ab-
normal blood urea nitrogen levels may be related
to the drug, when analyzed using the propensity
score method. A nested case-control study was de-
signed and performed to analyze the influencing
factors of suspected allergic reactions to SXN. The
study showed that patients with an allergy history
were more prone to allergic reactions (P<0.001),
and some medicine combinations could cause aller-
gic reactions.
CONCLUSION: These studies have established a
body of evidence on Xingxue® SXN safety, and pro-
vide a good model for Chinese medicine injection
for clinical safety. The Xingxue® SXN production
process and toxicology research indicate the safety
of the injection. However, the use of the injection is
not consistent with instructed clinical practice.
Xingxue® SXN causes ADRs perhaps from inappro-
priate usage or its pharmacological action. This in-
jection needs better RiskMAPs to ensure its clinical
safety.
© 2014 JTCM. All rights reserved.
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INTRODUCTION
Shuxuening injection (SXN) is a Traditional Chinese
Medicine (TCM) injection made from Yinxingye (Foli-
um Ginkgo) extract. Its main ingredients are flavo-
noids, terpenes, lactones, and alkaloids. There are nine
pharmaceutical factories producing SXN in China.
Xingxue® SXN is made by Heilongjiang ZBD Pharma-
ceutical Co., Ltd. The content per ampoule is 2 mL (or
5 mL), equivalent to 7.0 mg/ampoule (or 17.5 mg/am-
poule) of Yinxingye (Folium Ginkgo) extract (contain-
ing total flavonol glycosides 1.68mg/ampoule or 4.2mg/
ampoule; total bilobalide 0.28 mg/ampoule or 0.70 mg/
ampoule). The injection is effective at dilating blood
vessels and improving microcirculation. It is often used
to treat ischemic cardiovascular and cerebrovascular dis-
eases, including coronary heart disease, angina, cerebral
embolism, cerebral vasospasm, and other diseases. Its
dosage and administration are: intramuscular injection
at 2-4 mL, once or twice per day; or intravenous drip
at 20 mL per day, diluted with 5% glucose injection to
250 or 500 mL, or as directed by a physician. Adverse
drug reactions include: gastrointestinal discomfort,
phlebitis, allergic dermatitis, skin rash, allergic purpu-
ra, acute urticaria, chest tightness, palpitation, larynge-
al edema, dyspnea, chills, high fever, and anaphylactic
shock. Foreign reports showed that some similar prod-
ucts may cause bleeding, hypertension, allergic reac-
tions, and insomnia from central nervous system excita-
tion.
To improve the clinical safety and efficacy of Xingxue®
SXN, a series of preclinical studies and post-marketing
re-evaluation studies were conducted on this drug, and
strict quality control and active medicine risk manage-
ment were implemented to establish evidence on the
safety of Xingxue® SXN.1
MEDICINE QUALITY CONTROL
Quality control of raw herbs
Xingxue® SXN is made from the dried leaves of Yinx-
ingye (Folium Ginkgo). To maintain quality control
over Xingxue® SXN especially at its source, the pharma-
ceutical company performed an in-depth overall survey
on the raw herbs from species origin, planting regions,
field management, tree age, harvest time, drying, pack-
aging, and transportation through to storage. They also
specified the planting regions, harvest time, tree age,
and processing and drying methods, and developed a
full set of standard operation procedure documents re-
garding the planting, harvest, and storage maintenance
of Yinxingye (Folium Ginkgo). These measures guaran-
teed the safety, effectiveness, and uniformity of fin-
ished products.
Quality control of production process
The company implements strict quality control over
the production process. Its aim is to make sure more
than 60% of ingredients are identifiable in construc-
tion, and more than 80% ingredients are detectable in
the total solid of Xingxue® SXN. Among all ingredients
identifiable in construction, more than 90% are identi-
fiable in fingerprint chromatograms, which fulfills the
China Food and Drug Administration (CFDA) Basic
Technical Requirements of TCM and Natural Medici-
nal Injections, and satisfies the requirements for safety
re-evaluation of TCM injection. By high-performance
liquid chromatography, the company also performed a
fingerprint chromatogram study on the flavonoids and
lactones within Yinxingye (Folium Ginkgo), their ex-
tract, and finished products, and established internal
control standards.
Xingxue® SXN has full-process quality control, and suc-
cessfully passed a Good Manufacturing Practice 2010
certification. Integrated workshops, facilities, and appli-
ances ensure each batch of products is safe, effective,
and controllable and stable in quality. The company us-
es macroporous resin absorption technology to per-
form accurate, continuous testing, analysis, and opera-
tion; to carry out control in strict accordance with spec-
ifications; and to realize full-process real time quality
monitoring. This process allows for more precise mate-
rial control, avoids system errors arising out of manual
operations, significantly improves product quality and
productivity, reduces energy consumption, raises man-
agement level, and diminishes the difference between
different batches of drugs.
NONCLINICAL SAFETY AND
PHARMACOLOGICAL STUDIES
Special toxicological test
From March to May of 2005, the company commis-
sioned the Heilongjiang Institute for Food and Drug
Control for a series of safety tests. The results of the he-
molytic test indicated that Xingxue® SXN at a concen-
tration (take the 0.5 mL of Xingxue® SXN and 5% glu-
cose injection to 25 mL), caused no hemolysis or coag-
ulation effects in rabbits. In the allergy test, took 1.5 mL
Xingxue® SXN injection into glucose injection diluted
to 10 mL, and guinea pigs were intraperitoneally inject-
ed once every other day with diluents of Xingxue®
SXN at a dose of 0.5 mL/animal three consecutive
times. The guinea pigs were also administrated once a
day via ear veins with the diluents at a dose of 1.0 mL/
animal on the 14th and 21st days after the first intra-
peritoneal injection. There were no allergic reactions in
the guinea pigs. In the vascular irritation test, Xingxue®
SXN showed no local irritation when administered to
rabbits via ear veins at a concentration of 0.02 mL/mL
(take the 2 mL of Xingxue® SXN and 5% glucose injec-
tion to 100 mL). In the muscle irritation test, Xingxue®
SXN showed no irritation when administered to rab-
bits via the quadriceps femoris.
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POST-MARKETING CLINICAL
SAFETY STUDIES
Post-marketing research
From 2003 to 2005, two randomized controlled trials
were performed to evaluate the effectiveness and safety
of Xingxue® SXN in the treatment of stroke recovery
[Qi-Deficiency and Blood Stasis (QDBS)] and stroke
recovery in several hospitals. A total of 359 patients
were included in the trials. No adverse drug events oc-
curred, and treatment did not cause evident adverse ef-
fects on heart, liver, kidney, or blood markers.
Registry-based post-marketing clinical safety
monitoring study2
As one TCM injection under the registry-based
post-marketing clinical safety monitoring study, Xingx-
ue® SXN is covered by research from a National Sci-
ence and Technology Major Project for "Major New
Drugs Innovation and Development": Study on Key
Technologies of Post-marketing Evaluation for Chi-
nese Medicine (No. 2009ZX09502-030), presided by
Yanming Xie, researcher from the Institute of Basic Re-
search in Clinical Medicine, China Academy of Chi-
nese Medical Sciences. It is expected that a total of
30 000 patients will be recruited for this project. In De-
cember 2012, the ethics review of the Ethics Commit-
tee of the Institute of Basic Research in Clinical Medi-
cine, China Academy of Chinese Medical Sciences ap-
proved this project (Approval document No. 15) and
completed protocol registration in ClinicalTrials.gov,
an international clinical trial website (ID:
NCT01752946). The project is ongoing.
Spontaneous Reporting System (SRS) data analysis
Analysis on the case reports involving adverse drug re-
actions (ADRs) after using Xingxue® SXN from Janu-
ary 1, 2005 to December 31, 2012 from State Adverse
Drug Reaction Monitoring Centre showed that 3.93%
of ADRs were serious. The number and ADR ratio
were similar to all SXN ADRs from January 1, 2005 to
December 31, 2012.3 Additional ADRs were reported
with increased sales of the drug. Among all ADR pa-
tients, the group aged 60-74 contributed the highest
percentage. Overall, 96.45% of patients who experi-
enced ADRs followed the medicine specification items
of dosage. Among those patients who had ADRs,
63.23% suffered them on the same day that they used
the medicine. The ten most common symptoms of
ADRs were rashes, itching, suffocation, palpitations,
dizziness, chills, anaphylactoid reactions, nausea, phle-
bitis, and vomiting. The damage mainly involved the
whole body, skin, extremities, and nervous system. The
ten most common ADRs were analyzed using Report
Rate Proportion (PRR)4 and Bayesian Confidence
Propagation Neural Network (BCPNN).5 Control over
confounding factors was accomplished with the Gener-
alized Boosted Models (GBM) propensity score6weight-
ing method. The ADRs detected by PRR included diz-
ziness, phlebitis, and vomiting. The signals detected by
BCPNN were phlebitis.
The causes of ADRs may have some explanations. The
cause of dizziness is not clear, but may be because of se-
lective cerebrovascular expansion, a significant increase
in cerebral blood flow, or lower cerebral vascular resis-
tance. Patients can reduce infusion speed while admin-
istering the intravenous the drug to reduce dizziness.7
Phlebitis from SXN might be caused by high local
drug concentration, and the direct effect of drugs on
the walls of blood vessels or inhibition of platelet acti-
vating factors. It is suggested that SXN used in clinic
should be in accordance with the advised concentra-
tions, and to not administer the drug too quickly.8,9
The mechanism behind the vomiting ADR is not clear,
but it might be caused by SXN containing lactones
and alkaloids. Patients using the drug need to avoid
fasting, and slow the infusion rate to reduce gastrointes-
tinal reactions.
Hospital Information System (HIS) data analysis
An analysis was carried out on the clinical safety and ef-
fectiveness of all brands of SXN using data from 20
HIS comprehensive hospitals Grade Ⅲ, Level A, in
China.
A total of 48 445 inpatient cases using SXN were col-
lected. Patients using the medicine were mostly at the
age of 45 or above, accounting for 79.24% of the total.
Patients older than 65 years accounted for 42.48%. A
majority of patients were manual workers. The injec-
tion was used to treat coronary heart disease (known as
thoracic obstruction according to TCM) (accounting
for 14.80%), and cerebral infarction (known as stroke
in TCM) (accounting for 14.57% ). Patients meeting
the indications according to Western Medicine diagno-
sis accounted for 29.49%. Other patient diseases receiv-
ing the injection included hypertension (18.23%) and
diabetes (11.20%). The instructions on SXN state that
it can dilate blood vessels and improve microcircula-
tion, and is used to treat ischemic cardiovascular and
cerebrovascular diseases, including coronary heart dis-
ease, angina, cerebral embolism, cerebral vasospasm,
and other diseases. A Western Medicine physician's de-
cision to use SXN may be according to the drug's use
in clinical practice. However, traditional Chinese physi-
cians use the drug according to the instructions, or con-
sider the drug's efficacy for in adaptive patients using
TCM theory. The main administration route was intra-
venous injection, with a maximum dosage per session
of 15-20 mL. Patients receiving such a dosage account-
ed for 52.18% of the total, while 31.97% of patients
used a dosage in excess of 20 mL. The treatment gener-
ally lasted 3-7 days, and such cases accounted for
31.85% of total. The patients using the drug in a sol-
vent that met the requirements of the medicine specifi-
cation accounted for 34.00% of total. In clinical prac-
tice, the medicine was used in conjunction with aspirin
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to treat coronary heart disease and cerebral infarction.10
One analysis was conducted to investigate the effect of
SXN on hepatic and renal functions. The GBM pro-
pensity score method was used to eliminate confound-
ing factors. After balancing 71 covariates, it was found
that SXN might result in abnormal changes in blood
urea nitrogen. However, no significant effects were
found on alanine aminotransferase, aspartate amino-
transferase, and serum creatinine. The same method
was also used to analyze the effect of SXN on hepatic
and renal function in the event that it was used at an
over-recommended dosage or for a period in excess of
general drug duration (3-7 days). Significant effects
were still not found on hepatic and renal functions.11
A nested case-control study was designed and per-
formed to analyze the influencing factors of suspected
allergic reactions to SXN. There were 98 patients who
terminated their use of SXN within 24 h to receive
dexamethasone injection instead. After termination of
SXN, they were no longer considered as patients with
suspected allergic reactions to SXN. This group was
compared with the control group, which consisted of
patients without possible allergic reactions, in a ratio of
1∶4. Using Chi-square test and logistic regression, the
result showed that those who had an allergy history
were more prone to allergic reactions (P<0.001), and
the suspected risk factors leading to allergic reaction in-
cluded the use of dopamine (OR=11.352), magnesium
aspartate (OR=14.518), lidocaine (OR=5.897), vitamin
B6 (OR=4.910), omeprazole (OR=8.725), and vitamin
B12 (OR=6.793). Considering the limited data, fur-
ther analyses are needed to verify whether allergic reac-
tions have actually taken place. Alternatively, prospec-
tive studies may be carried out to validate the results
this analysis.12
Literature analysis
After searching the Chinese Biomedical Literature Da-
tabase, Wanfang Database, Chinese National Knowl-
edge Infrastructure Database, and Chinese Science and
Technology Periodical Database for articles concerning
SXN using a series of inclusion and exclusion criteria,
748 articles were determined as the subject articles. On-
ly five articles were ADR case reports of the Xingxue®
SXN made by Heilongjiang ZBD Pharmaceutical Co.,
Ltd., and no patients died. After symptomatic treat-
ment, patient symptoms were relieved or disappeared.13
The safety articles of the Xingxue® SXN are too sparse
to statistically analyze.
MEDICINE RISKMANAGEMENT
PROGRAM
Heilongjiang ZBD Pharmaceutical Co., Ltd., has put
in place a series of Risk Minimization Action Plans
(RiskMAPs) for Xingxue® SXN, established a study
panel for safety reevaluation of TCM injection, and a
medicine safety panel responsible for the identification,
evaluation, and management of drug risks. The compa-
ny has also established product in-process control, lo-
gistics and market regulation, active information collec-
tion, timely reporting, and periodical review and analy-
sis. This can allow early discovery of dangerous signals
of drug production, allow for corrective actions and
guidance on the improvement of production, and re-
port drug safety information to competent depart-
ments and provide reasonable advice on clinical appli-
cation. The company also entrusted universities and re-
search institutions in China to perform a series of stud-
ies on the material fundamentals, toxicology, pharma-
codynamics, and clinical studies on Xingxue® SXN.
The company has established the fingerprint chromato-
grams of all raw medicinal materials, extracts and fin-
ished products, and performed relevance analyses. The
company also periodically organizes after-effect evalua-
tion of RiskMAPs.
CONCLUSION
This review summarized the safety research on Xingx-
ue® SXN produced by Heilongjiang ZBD Pharmaceuti-
cal Co., Ltd. Analysis on the drug included the selec-
tion of raw herbs, quality control process of drug pro-
duction, drug toxicology research, post-marketing liter-
ature review, and analysis of SXN adverse reactions da-
ta from SRS, and its clinical characters. Large-scale pro-
spective safety monitoring, and drug RiskMAP imple-
mentation have also been performed. This study can
provide a summary of the foundation of evidence on
the clinical safety of Xingxue® SXN, and the basis for
its safe clinical application.
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